Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/105880FUSION GENE, RECOMBINANT NOVEL CORONAVIRUS HIGH-EFFICIENCY IMMUNE DNA VACCINE, CONSTRUCTION METHOD THEREFOR AND USE THEREOF
WO 27.05.2022
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No PCT/CN2021/131786 Applicant AURORA GENEVAC BIOTECH CO., LTD. Inventor YU, Jiyun
A fusion gene, a recombinant novel coronavirus high-efficiency immune DNA vaccine, a construction method therefor and use thereof. The immune DNA vaccine ZD-nCor19 provided therein uses RBD protein, segment 301-538aa of the S2 subunit and segment 138-369aa of the N protein of the novel coronavirus as target antigens, and has a specific immune synergism molecule introduced at a suitable position, and thus can simultaneously efficiently induce humoral immunity and cellular immunity, and can avoid safety problems associated with ADE that may be generated by the full-length S protein and the full-length N protein, thereby achieving dual effects of prevention and treatment.
2.WO/2022/109164DEVELOPMENT OF A NOVEL ELISA-BASED POINT-OF-CARE ANTIGEN TEST FOR SARS-COV-2
WO 27.05.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/059934 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor SHINO, Yusaku Michael
Aspects of the present disclosure relate to methods and systems designed to utilize antibodies and viral inactivating / lysis agents to detect SARS-CoV-2 on a microfluidic channel-based platform, for example in samples obtained from nasal swabs taken from infected individuals. The rapid and accurate point of care COVID-19 diagnostic tests that are disclosed herein can transform medical professional's testing capabilities, and in this way improve the ability to control the COVID-19 pandemic.
3.WO/2022/104465SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS DNA VACCINES
WO 27.05.2022
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CA2021/051633 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
DNA vaccine vectors composed of a vector portion and an antigen-coding portion that comprises a nucleic acid sequence encoding a severe acute respiratory syndrome coronavirus (SARS-CoV) antigen are provided. The DNA vaccines of the present disclosure are able to trigger an immune response towards SARS-CoV-2.
4.WO/2022/109484NEUTRALIZING VACCINES AGAINST HUMAN CORONAVIRUS
WO 27.05.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/060600 Applicant WISCONSIN ALUMNI RESEARCH FOUNDATION Inventor TALAAT, Adel M.
The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated DNA vaccine compositions and viral vaccine compositions that encode a SARs-CoV-2 spike (S) protein, a SARs-CoV-2 nucleocapsid (N) protein, or both the S protein and the N protein. Additionally, the present invention provides methods in which the disclosed vaccines are administered to a subject to induce an immune response against SARS-CoV-2.
5.WO/2022/103929NUCLEIC ACIDS, PROTEINS, AND VACCINES OF SARS-COV-2
WO 19.05.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/058929 Applicant CITY OF HOPE Inventor KWAK, Larry, W.
Provided herein are, inter alia, SARS-CoV-2 spike (S) proteins; nucleic acids and plasmids encoding the proteins; vaccines and pharmaceutical compositions comprising the proteins, nucleic acids, or plasmids; methods for treating or preventing COVID-19; and methods for increasing immunity or providing acquired immunity to SARS-CoV in a subject.
6.WO/2022/102894CORONAVIRUS VACCINE USING REPLICATION-DEFICIENT ADENOVIRUS THAT SIMULTANEOUSLY EXPRESSES CORONAVIRUS SPIKE PROTEIN AND NUCLEOCAPSID PROTEIN
WO 19.05.2022
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/KR2021/006981 Applicant BIOLEADERS CORPORATION Inventor CHOI, Joung Woo
The present invention relates to a recombinant adenovirus in which coronavirus spike protein and nucleocapsid protein are expressed in the form incorporated into the E1 region and the E3 region of a replication-deficient adenovirus, and a coronavirus vaccine using same. A vaccine composition according to the present invention can induce a humoral immune response and a cell-mediated immune response, thereby evoking immune responses to COVID-19.
7.WO/2022/099411DEUTERIUM-STABILISED RIBONUCLEIC ACID (RNA) MOLECULES DISPLAYING INCREASED RESISTANCE TO THERMAL AND ENZYMATIC HYDROLYSIS, AQUEOUS COMPOSITIONS COMPRISING STABILIZED RNA MOLECULES AND METHODS FOR MAKING SAME
WO 19.05.2022
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No PCT/CA2021/051598 Applicant DEUTRAMED SOLUTIONS LTD. Inventor GRIS, Pavel
The invention relates to the field of RNA stabilisation, and more particularly to the use of deuterium oxide (D2O) during storage and/or synthesis of RNA molecules. Described herein are deuterium-stabilised ribonucleic acid (RNA) molecules that display an increased resistance to thermal and enzymatic hydrolysis. Also described are aqueous compositions comprising stabilized RNA molecules and methods for making same. The invention is particularly useful for in the manufacture or RNA-based therapeutics, such as mRNA vaccines, to render them less sensitive to temperature fluctuations.
8.WO/2022/102652NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE
WO 19.05.2022
Int.Class C07H 15/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
02Acyclic radicals, not substituted by cyclic structures
04attached to an oxygen atom of a saccharide radical
Appl.No PCT/JP2021/041323 Applicant DAIICHI SANKYO COMPANY, LIMITED Inventor KOBAYASHI Hiroyuki
The present invention provides a novel compound, which has a TLR4 activating effect and is usable as an immune activator or adjuvant in vaccine or allergen immunotherapy, or a pharmaceutically acceptable salt thereof. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. [In formula (I), X, Y, Z and n are each as defined in the description.]
9.WO/2022/101302ANTIBODIES CONJUGATED OR FUSED TO THE RECEPTOR-BINDING DOMAIN OF THE SARS-COV-2 SPIKE PROTEIN AND USES THEREOF FOR VACCINE PURPOSES
WO 19.05.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/EP2021/081303 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor LEVY, Yves
SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells. The present invention thus relates to antibodies that are directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to the receptor-binding domain of the Sars-Cov-2 spike protein.
10.20220152195METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS
US 19.05.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17526698 Applicant Leonhardt Ventures LLC Inventor Howard J. Leonhardt

Described are methods of treating a mammalian subject who is intending to undergo exposure to an inoculant comprising a virus, polynucleotide(s) encoding at least a portion of the virus, and/or epitope(s) of the virus, the method including administering at least one bioelectric signal to the subject before exposure to the inoculant in such a manner as to increase the subject's T cell count and/or T helper cell count. Also described are methods of treating a mammalian subject undergoing a viral infection, the method comprising: administering bioelectric signals to the subject so as to upregulate expression of SDF-1 in the subject, upregulate expression of PDGF in the subject, upregulate stem cell proliferation in the subject, and upregulate expression of klotho in the subject; reducing inflammation in the subject, and administering bioelectric signals to the subject so as to stimulate regeneration of the subject's lungs and blood vessels.